
- MDL 28170
- PD 150606
- Acetyl-Calpastatin (184-210) (human)
- Calpain Inhibitor I, ALLN
- E-64
- PD 151746
Calpain Inhibitor II, ALLMCalpain inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure

Related Biological Data

Related Biological Data

Description | Calpain Inhibitor II, ALLM is a cell-permeable inhibitor of calpain I, calpain II, cathepsin L and cathepsin B with Ki values of 120 nM, 230 nM, 0.6 nM and 100 nM, respectively. | |||||
Targets | calpain I | calpain II | cathepsin L | cathepsin B | ||
IC50 | 120 nM (Ki) | 230 nM (Ki) | 0.6 nM (Ki) | 100 nM (Ki) |
Cell experiment [1]: | |
Cell lines | Acute lymphoblastic leukemia (ALL) cell lines (ALL-1, RS4;11, and JURKAT) and non-Hodgkin’s lymphoma (NHL) cell lines (RAMOS and DAUDI) |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reaction Conditions | 50 or 100 μM; 24 hrs |
Applications | At the dose of 50 or 100 μM, Calpain inhibitor II induced apoptosis in ALL (ALL-1, RS4;11, and JURKAT) and NHL (RAMOS and DAUDI) cell lines. Additionally, studies had shown that neither BTK nor LYN were required for Calpain inhibitor II induced apoptosis. Calpain inhibition with Calpain inhibitor II had been demonstrated to activate an apoptosis-promoting caspase system. |
References: [1]. Zhu DM1, Uckun FM. Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin"s lymphoma cells as well as some solid tumor cells. Clin Cancer Res. 2000 Jun;6(6):2456-63. |

Calpain Inhibitor II, ALLM Dilution Calculator
calculate

Calpain Inhibitor II, ALLM Molarity Calculator
calculate
Cas No. | 136632-32-1 | SDF | Download SDF |
Synonyms | N-Acetyl-Leu-Leu-Methional | ||
Chemical Name | 2-acetamido-4-methyl-N-[4-methyl-1-[(4-methylsulfanyl-1-oxobutan-2-yl)amino]-1-oxopentan-2-yl]pentanamide | ||
Canonical SMILES | CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCSC)C=O)NC(=O)C | ||
Formula | C19H35N3O4S | M.Wt | 401.57 |
Solubility | ≥14.85mg/mL in DMSO | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Calpain inhibitor II (CPI-2) is a cell-permeable inhibitor of calpain I, calpan II, cathepsin L and cathepsin B.
Calpain inhibitor II 2 at 50 or 100 μM has shown to induce apoptosis in (acute lymphoblastic leukemia) ALL (ALL-1, RS4;11, and JURKAT) and (non-Hodgkin’s lymphoma) NHL (RAMOS and DAUDI) cell lines, as measured by MC540 single fluorescence. Additionally, studies have shown that neither BTK nor LYN were required for calpain inhibitor II induced apoptosis. Calpain inhibition with calpain inhibitor II has been demonstrated to induce apoptosis-promoting caspase system [1]. Unlike calpain inhibitor I, calpain inhibitor II cannot inhibit NFkB and sensitize DLD1-TRAIL/R cells to the TRAIL protein [2].
References:[1] Zhu DM1, Uckun FM. Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin"s lymphoma cells as well as some solid tumor cells. Clin Cancer Res. 2000 Jun;6(6):2456-63.[2] Zhu H1, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, Chiao P, Fang B.Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther. 2004 May;9(5):666-73.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
当抗体结合到示踪剂上时,340nm的激发光激发铕标分子,导致能量转移到Alexa Fluor 647染料上,结果产生665nm的发射光。荧光的强度与样品中的cAMP含量成反比。
本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体,激动剂刺激导致665nm的荧光强度降低,而拮抗剂则可以逆转这一效应;对于偶联Gαi的受体,在激动剂刺激的同时用forskolin刺激cAMP产生,那么激动剂则抑制forskolin诱导的cAMP的生成,因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。
该试剂盒的灵敏度很高,室温下反应在20h内是稳定的。本试剂盒适用于在384孔板中进行24μl的微量分析。
2.保存条件
避光2~4℃保存,过期时间见装。
3.盒内试剂
cAMP标准品:1管,1ml。(50μM)
生物素标记的cAMP(b-cAMP):1管,25μl。
铕标的抗生物素蛋白链菌素:1管,25μl。
荧光标记的cAMP抗体:1管,40μl。
检测缓冲液:1瓶,25ml。
4.需要自配的其他溶液
l Hank’s balanced salt solution (HBSS): NaCl 8.0g、CaCl2 0.14g、KCl 0.4g、 KH2PO4 0.06g、Na2HPO4?7H2O0.09g、MgCl2.6H2O0.10 g、MgSO4.7H2O0.10 g、NaHCO30.35g、葡萄糖1.0g,加H2O至 1000ml (用7.5%NaHCO调节PH值=7.4)
l Versene消化液(1L):EDTA 0.372 g,NaCl 8.0g,KCl 0.20 g,KH2PO40.20g,Na2HPO4 1.15 g,D-glucouse 0.2 g,pH 7.4
l HEPES缓冲液(1mol/L):取2.383gHEPES溶于10ml去离子水中。
l 7.5%BSA溶液:取0.75gBSA溶于10ml去离子水中
l 0.5M IBMX溶液:11.11mg IBMX溶于100μl DMSO中,-20℃冻存。
l 刺激缓冲液(SB):14 ml HBSS(1×)+75μlHEPES(1mol/L)+200μlBSA (7.5%)。(注:在测定细胞cAMP时,反应缓冲液中要加入IBMX 0.5mmol/L)
l 吗啡贮存液(10mM):盐酸吗啡37.585mg溶于10ml生理盐水中,0.22μm滤膜过滤除菌,4℃保存备用。
l 纳络酮母液(100mM):纳络酮4mg溶于100μl 生理盐水中,用时工作液按照1:500稀释,溶剂为含有IBMX的反应缓冲液。
2.微孔板:选择实验所需的板条数。剩余不用的部分随同干燥剂密封放回原袋。 1.包被有抗抑制素bB亚单位抗体的微孔板(Anti-InhibinB-CoatedMicrotitrationStrips):96孔,2-8ºC下密封保存。
2.标准品A/样本稀释液(InhibinBStandardA/SampleDiluent):2ml×1瓶,胎牛血清,含0pg/mL二聚体抑制素B。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
3.标准品B-G(InhibinBStandardsB-G):1ml×6瓶,胎牛血清,含二聚体抑制素B的浓度为10,30,100,250,500,1000pg/mL。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
4.质控(InhibinBControls):1ml×2瓶,浓度I、II,胎牛血清,含低浓度和高浓度的抑制素A二聚体。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
5.样本稀释液A(InhibinBSampleBufferA):10ml×1瓶,2-8ºC下保存。
6.样本稀释液B(InhibinBSampleBufferB):10ml×1瓶,2-8ºC下保存。
7.抗体-生物素结合物(InhibinBAntibody-BiotinConjugate)(即用型):10ml×1瓶,含生物素标记的抗抑制素a亚单位抗体。2-8ºC下保存。
8.酶结合物(浓缩)(Streptavidin-EnzymeConjugate)(即用型):10ml×1瓶,含链霉和素-辣根过氧化物酶结合物。2-8ºC下保存。
9.TMB底物溶液(TMBChromogenSolution):15ml×1瓶,2-8ºC下保存。
10.终止液(StoppingSolution):15ml×1瓶,为0.2M的硫酸。2-8ºC下保存。
11.浓缩洗液(WashConcentrate):100ml×1瓶,2-8ºC下保存。 操作前所有试剂都应平衡至室温(~25ºC)并充分混匀。标准品、质控及待测样本需同时做双份。
1.取出实验所需板条,并记录各孔位置。
2.在对应的孔中加入标准品、质控及待测样本各50ul。
3.每孔加入25ul样本稀释液A。
4.每孔加入25ul样本稀释液B。
5.封板,以300-400rpm速度震荡,室温下过夜(14-18小时)。
6.洗板3次,在吸水纸上拍干。
7.每孔加入50ul抗体-生物素结合物。
8.封板,以500-700rpm速度震荡,室温下孵育1.5小时。
9.洗板6次,在吸水纸上拍干。
10.每孔加入50ul链霉和素-辣根过氧化物酶结合物。
11.封板,以500-700rpm速度震荡,室温下孵育20分钟。
12.洗板6次,洗完最后一次以后,将洗液在孔内停留15分钟再除去。在吸水纸上拍干。
13.在每孔中加入100ulTMB底物溶液。
14.以500-700rpm速度震荡,室温下避光孵育15-30分钟。
15.每孔加入100ul终止液。
16.30分钟内在450nm处读数。
注:必须以零标准作空白。如果能做到双波长测定,可在600或620nm处读数,将600(620)nm吸收值从450nm处减去,这样可以减少光学误差。 使用血清样本,静脉穿刺术采集血液。样本于2-8ºC可保存24小时,-20ºC或以下可保存30天。避免反复冻融样本。不应采用溶血或脂血的样本。冰冻的样本在实验前应解冻,并充分混匀。向左转|向右转
Vanderbilt-Ingram癌症中心的主任HalMoses博士和他的实验室研究人员,于1985年辨识出TGF-b,这种物质具有生长刺激物和生长抑制的作用。从那段时间之后,TGF-b在直肠、乳房和其他癌症中所扮演的角色便获得研究人员的广泛研究。
如今Vanderbilt-Ingram癌症中心的一组研究人员,发现了TGF-b矛盾的生物学作用之线索。他们的研究结果将发表于2003年12月的NationalAcademyofScience网络版,网址为www.pnas.org,这篇研究将于2003年12月稍后发表于纸本中。
TGF-b通常会抑制细胞生长,但是,很多实质性肿瘤会过度表现TGF-b,而使细胞不完全被抑制,事实上,有时候它们因为TGF-b的讯息使肿瘤细胞的生长比正常细胞更快。
TGF-b使用多种标记途径将它的指令送达细胞核心,已知大约有至少四条途径以上。研究人员去除一种特殊蛋白质组成的TGF-b标记:Rho-ROCK。细胞便不再受到抑制,而再度开始生长。
[信息来源:中国科技信息网站]
认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他站友认领”
MaggotsFasterThanScalpelinWoundDebridement
December19,2011—Maggotdebridementtherapy(MDT)appearstobemoreeffectiveforwounddebridementcomparedwithconventionaltherapy,butonlyat1week;afterthattime,anothertypeofdressingshouldbeused,newresearchsuggests.
KristinaOpletalovà,MD,fromtheDepartmentofDermatology,UniversityofCaen,France,andcolleaguespublishedonlineDecember19intheArchivesofDermatology.
MedicalmaggotswereapprovedbytheUSFoodandDrugAdmiNISTrationasamedicaldeviceforwounddebridementin2004.Accordingtotheresearchers,useofmaggotsintreatingwoundsisassociatedwitheffectivewounddebridement,antibacterialeffects,andstimulationofwoundhealing.
However,theypointout,"[r]elativelyfewclinicalstudieshavebeenconductedandtheresultsarenotclear,partlyowingtomethodologicassessmentproblems."
InthecurrentProspective,randomizedcontrolled,phase3clinicaltrial,theresearcherssoughttodeterminetheefficacyofbaggedlarvaeonwounddebridementincomparisonwithconventionaltreatment.
TheprimaryobjectivewastocomparethemeanpercentageofsloughinwoundstreatedwithMDTwiththatofconventionaltreatmentatday15.Thestudyincluded119patientswithanonhealing,sloughywoundthatwas40cm2orsmallerandlessthan2cmdeep.Patientsalsohadananklebrachialindexof0.8orhigher.
Treatmentwasadministeredduringa2-weekhospitalstay.Conventionaltreatmentconsistedofsurgicaldebridement3timesaweekwithascalpel,withuseoftopicalanesthesia.TheMDTwasadministeredusinganencloseddressing(Vitapad,BioMondeLaboratories)containing80sterilemaggots.Atdischarge,aconventionaldressingwasapplied,andpatientswerefollowed-upatday30.
DebridementbyMDTwassignificantlyfasterthansurgicaldebridementduringthefirstweekoftreatment,reachingthesamelevelthecontrolgroupreachedatday15.NobenefitforMDTcomparedwithconventionaltreatmentinhealingrateswasobserved.Atday8,54.5%intheMDTgroupvs66.5%inthecontrolgroup(P=.04)hadevidenceofsloughandwoundhealing.However,byday15,themeanpercentageofsloughwas55.4%intheMDTgroupand53.8%inthecontrolgroup(P=.78).
"AthoughMDTshowsnosignificantbenefitatday15comparedwithconventionaltreatment,debridementbyMDTissignificantlyfasterandoccursduringthefirstweekoftreatment,"theresearchersconclude."Becausethereisnobenefitincontinuingthetreatmentafter1week,anothertypeofdressingshouldbeusedafter2or3applicationsofMDT."
Painscoresweresimilarandmildinbothgroups,althoughincontrasttoconventionaltreatment,MDTwasperformedwithouttopicalanesthesia.
Accordingtotheresearchers,noneofthepatientswerereticentaboutundergoingMDT."[A]crawlingsensationonthewoundwasrarelyandalmostequallynotedinbothgroups,revealingthatthesensationwassubjective,"Dr.Opletalovàandcolleaguespointout.
TwoquestionsregardingMDTremainunanswered,theauthorsnote."Candebridementbeimprovedusingmoremaggotsperdressing?Ifso,wouldthesedressingsbemorepainful?Furtherstudiesareneededtoanswerthesequestions."
ThestudywassupportedbygrantsfromtheClinicalResearchHospitalProgramandfromtheFrenchSocietyofDermatology.Theauthorshavedisclosednorelevantfinancialrelationships.
成纤维细胞生长抑制试剂盒—FibrOut™ 是由多种生化复合物组成的混合物、抗体或特殊的试剂。它能够抑制成纤维细胞过度增长或污染从而有效地增加靶细胞的产量。每种成纤维细胞生长抑制试剂盒都可定制到特定组织和特定细胞,经验证可与对应的PrimaCellTM系统高效协同工作,可为您带来每一类原代细胞培养的最佳结果。每种成纤维细胞生长抑制试剂盒都配备了最合适的缓冲液。
FibrOut™ 是一种包含几种生化复合物和试剂的完整系统,它在原代细胞培养中能抑制成纤维细胞增殖,从而促进靶细胞生长。每种成纤维细胞生长抑制试剂盒都可定制到特定组织和特定细胞,经验证可与对应原代细胞培养试剂盒-PrimaCellTM高效协同工作,可为您带来每一类原代细胞培养的最好结果。每种成纤维细胞生长抑制试剂盒都配备了最合适的缓冲液。成分包括 (1)胰蛋白酶;(2)胶原酶;(3)D-缬氨酸;(4)顺式羟基脯氨酸;(5)硫柳汞;(6)苯巴比妥;(7)系列血清替代品;(8)抗中胚层带抗体。
参考文献:
1. Cancer Res. 2010 May 1;70(9):3537-46,Epub 2010 Apr 20. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Bassères DS, Ebbs A, Levantini E, Baldwin AS.
2. Nat Commun. 2013;4:1795. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, Wang J, Jin T, Zhang H, Dai J, Krebsbach PH, Keller ET, Pienta KJ, Taichman RS.
3. Mol Biol Cell. 2012 Jul;23(14):2755-69. Calcium-calmodulin kinase I cooperatively regulates nucleocytoplasmic shuttling of CCTα by accessing a nuclear export signal. Agassandian M, Chen BB, Pulijala R, Kaercher L, Glasser JR, Mallampalli RK.展开
该试剂盒是一种时间分辨的荧光共振能量转移免疫分析,该反应是一个竞争免疫反应,即铕标的cAMP示踪复合物与体系中的cAMP竞争结合标有Alexa Fluor 647染料的cAMP抗体。铕标cAMP示踪复合物是通过Biotin标记的cAMP与铕标的抗生物素蛋白链菌素(streptavidin)与抗体的复合物紧密结合产生的。
当抗体结合到示踪剂上时,340nm的激发光激发铕标分子,导致能量转移到Alexa Fluor 647染料上,结果产生665nm的发射光。荧光的强度与样品中的cAMP含量成反比。
本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体,激动剂刺激导致665nm的荧光强度降低,而拮抗剂则可以逆转这一效应;对于偶联Gαi的受体,在激动剂刺激的同时用forskolin刺激cAMP产生,那么激动剂则抑制forskolin诱导的cAMP的生成,因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。
该试剂盒的灵敏度很高,室温下反应在20h内是稳定的。本试剂盒适用于在384孔板中进行24μl的微量分析。
2.保存条件
避光2~4℃保存,过期时间见外包装。
3.盒内试剂
cAMP标准品:1管,1ml。(50μM)
生物素标记的cAMP(b-cAMP):1管,25μl。
铕标的抗生物素蛋白链菌素:1管,25μl。
荧光标记的cAMP抗体:1管,40μl。
检测缓冲液:1瓶,25ml。
4.需要自配的其他溶液
l Hank’s balanced salt solution (HBSS): NaCl 8.0g、CaCl2 0.14g、KCl 0.4g、 KH2PO4 0.06g、Na2HPO4?7H2O0.09g、MgCl2.6H2O0.10 g、MgSO4.7H2O0.10 g、NaHCO30.35g、葡萄糖1.0g,加H2O至 1000ml (用7.5%NaHCO调节PH值=7.4)
l Versene消化液(1L):EDTA 0.372 g,NaCl 8.0g,KCl 0.20 g,KH2PO40.20g,Na2HPO4 1.15 g,D-glucouse 0.2 g,pH 7.4
l HEPES缓冲液(1mol/L):取2.383gHEPES溶于10ml去离子水中。
l 7.5%BSA溶液:取0.75gBSA溶于10ml去离子水中
l 0.5M IBMX溶液:11.11mg IBMX溶于100μl DMSO中,-20℃冻存。
l 刺激缓冲液(SB):14 ml HBSS(1×)+75μlHEPES(1mol/L)+200μlBSA (7.5%)。(注:在测定细胞cAMP时,反应缓冲液中要加入IBMX 0.5mmol/L)
l 吗啡贮存液(10mM):盐酸吗啡37.585mg溶于10ml生理盐水中,0.22μm滤膜过滤除菌,4℃保存备用。
l 纳络酮母液(100mM):纳络酮4mg溶于100μl 生理盐水中,用时工作液按照1:500稀释,溶剂为含有IBMX的反应缓冲液。

